Clinical applications of Ashwagandha plant in depression and anxiety
Abstract
Ashwagandha is an adaptogenic herb that has been long used in traditional Indian medicine and has garnered attention in modern medicine in recent years. Known for its ability to restore balance in the body due to its adaptogenic properties, Ashwagandha is believed to offer potential benefits in addressing anxiety and depression, which are growing public health concerns in modern society. The bioactive components found in Ashwagandha, particularly withanolides, may contribute to reducing symptoms of anxiety and depression through various biological mechanisms that affect the nervous system. This can involve the regulation of neurotransmitters, anti-inflammatory effects, and support for stress coping mechanisms. The fact that Ashwagandha tends to cause fewer side effects compared to conventional antidepressants and anxiolytic drugs, along with its broad mechanism of action as a natural adaptogen, presents a significant advantage in terms of potential future therapeutic options. Many studies in the literature suggest that Ashwagandha could serve as a natural adjunct in these areas. However, more clinical trials and long-term effect analyses are necessary to fully evaluate this potential. This review aims to lay the groundwork for future research by assessing current literature on the effectiveness of Ashwagandha in addressing anxiety and depression.
Keywords
Ethical Statement
ETİK KURUL BELGESİ GEREK OLMADIĞI BEYAN EDİLMİŞTİR
References
- Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43:471-81.
- Craske MG, Stein MB, Eley TC, Milad MR, Holmes A, Rapee RM et al. Anxiety disorders. Nat Rev Dis Primers. 2017;4:17024.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Arlington, American Psychiatric Publishing, 2013.
- Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA, Ahbabi AA. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Curr Psychiatry. 2023;30:44.
- Garber J, Brunwasser S, Zerr A, Schwartz K, Sova K, Weersing V. Treatment and prevention of depression and anxiety in youth: test of cross-over effects. Depress Anxiety. 2016;33:939-59.
- Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytother Res. 2018;32:1147-62.
- Sarris J, Ravindran A, Yatham L, Marx W, Rucklidge J, McIntyre R et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Task force. World J Biol Psychiatry. 2022;23:424-55.
- Speers A, Cabey K, Soumyanath A, Wright K. Effects of Withania somnifera (Ashwagandha) on stress and the stress- related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol. 2021;19:1468-95.
- Panossian A, Efferth T, Shikov A, Pozharitskaya O, Kuchta K, Mukherjee P et al. Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases. Med Res Rev. 2021;41:630-703.
- Alam N, Hossain M, Khalil M, Moniruzzaman M, Sulaiman S, Gan S. Recent advances in elucidating the biological properties of Withania somnifera and its potential role in health benefits. Phyto Chem Rev. 2012;11:97-112.
